Hybio Pharmaceutical Co., Ltd.
300199
주식 순위
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
주가
$3.69
시가총액
$3.11B
변동 (1일)
-7.75%
변동 (1년)
21.56%
국가
CN
거래 Hybio Pharmaceutical Co., Ltd. (300199)
카테고리
Healthcare
Hybio Pharmaceutical Co., Ltd. (300199)의 수익
Jun 2026 기준 수익 TTM: $23.66M
Hybio Pharmaceutical Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $23.66M입니다. 2024년에 회사는 $-22.25M의 수익을 올렸으며 이는 2023년의 수익 $-72.20M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Hybio Pharmaceutical Co., Ltd.의 수익 기록 (2007 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $23.66M | 157.76% |
| 2025 | $9.18M | -141.26% |
| 2024 | $-22.25M | -69.18% |
| 2023 | $-72.20M | 33.59% |
| 2022 | $-54.05M | -1,119.96% |
| 2021 | $5.30M | -105.88% |
| 2020 | $-90.05M | -29.65% |
| 2019 | $-128.00M | 163.83% |
| 2018 | $-48.52M | -190.05% |
| 2017 | $53.88M | 20.99% |
| 2016 | $44.53M | -14.53% |
| 2015 | $52.11M | 73.20% |
| 2014 | $30.08M | 23.42% |
| 2013 | $24.38M | 44.61% |
| 2012 | $16.86M | 13.35% |
| 2011 | $14.87M | 79.07% |
| 2010 | $8.30M | 48.60% |
| 2009 | $5.59M | 70.78% |
| 2008 | $3.27M | 57.76% |
| 2007 | $2.07M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $3.62B | 15,188.96% |
DE
|
|
| $3.40B | 14,289.34% |
DE
|
|
| $1.72B | 7,183.94% |
JP
|
|
| $930.30M | 3,831.42% |
CH
|
|
| $1.76B | 7,356.94% |
IN
|
